文献速递肝病

非酒精性脂肪性肝病(NAFLD)中排除肝硬化的临床预测规则比较

Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD).
PubMed 文献 · Aliment Pharmacol Ther · 2022-03-17

该横断面分析纳入美国NASH临床研究网络和英国纽卡斯尔队列的成年患者,比较多种临床预测规则在排除活检证实的NAFLD肝硬化中的表现。美国队列肝硬化比例为147/1483(10%),英国队列为59/494(12%)。所有规则阴性预测值均较高,FIB-4和NAFLD纤维化评分准确度最高。作者认为这些规则可用于初级保健识别不太可能患肝硬化者,以保障高危患者转诊专科。

要点

  • 美国队列147/1483(10%)有肝硬化,FIB-4和NAFLD纤维化评分AUROC为0.84-0.86。
  • 英国队列59/494(12%)有肝硬化,FIB-4和NAFLD纤维化评分AUROC为0.87-0.89。
  • 所有预测规则阴性预测值高,美国队列为0.95-0.97,英国队列为0.92-0.96。

核心结论

  • 这项大型多中心国际数据集的横断面分析显示,现有临床预测规则在选用合适截断值时能较好地排除肝硬化。
  • 作者认为这些临床预测规则可用于初级保健,识别尤其是不太可能患肝硬化的白人、女性、小于65岁患者,以使高危患者保持获得专科诊疗的机会。

研究设计与样本

  • 横断面分析,纳入美国NASH临床研究网络和英国纽卡斯尔队列的成年患者。
  • 入组时收集临床和实验室数据,入组1年内进行肝活检。
  • 美国队列肝硬化比例为147/1483(10%),英国队列为59/494(12%)。
  • 各评分排除肝硬化的最佳截断值来自美国队列,并在英国队列中评估。

主要发现

  • 所有预测规则阴性预测值相似且较高,美国队列为0.95-0.97,英国队列为0.92-0.96。
  • 美国队列中FIB-4和NAFLD纤维化评分对肝硬化的区分准确度最高,AUROC为0.84-0.86。
  • 英国队列中FIB-4和NAFLD纤维化评分对肝硬化的预测准确度最高,AUROC为0.87-0.89。

关键数值与推荐

  • 美国队列肝硬化比例为147/1483(10%),英国队列为59/494(12%)。
  • 美国队列所有预测规则阴性预测值为0.95-0.97,英国队列为0.92-0.96。
  • 美国队列FIB-4和NAFLD纤维化评分AUROC为0.84-0.86,英国队列为0.87-0.89。

临床怎么用

  • 作者认为这些临床预测规则可用于初级保健,识别尤其是不太可能患肝硬化的白人、女性、小于65岁患者,以使高危患者保持获得专科诊疗的机会。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Patients with nonalcoholic fatty liver disease (NAFLD) cirrhosis benefit from referral to subspecialty care. While several clinical prediction rules exist to identify advanced fibrosis, the cutoff for excluding cirrhosis due to NAFLD is unclear. This analysis compared clinical prediction rules for excluding biopsy-proven cirrhosis in NAFLD. METHODS: Adult patients were enrolled in the NASH Clinical Research Network (US) and the Newcastle Cohort (UK). Clinical and laboratory data were collected at enrolment, and a liver biopsy was taken within 1 year of enrolment. Optimal cutoffs for each score (eg, FIB-4) to exclude cirrhosis were derived from the US cohort, and sensitivity, specificity, positive predictive value, negative predictive value and AUROC were calculated. The cutoffs were evaluated in the UK cohort. RESULTS: 147/1483 (10%) patients in the US cohort had cirrhosis. All prediction rules had similarly high NPV (0.95-0.97). FIB-4 and NAFLD fibrosis scores were the most accurate in characterising patients as having cirrhosis (AUROC 0.84-0.86). 59/494 (12%) patients in the UK cohort had cirrhosis. Prediction rules had high NPV (0.92-0.96), and FIB-4 and NAFLD fibrosis score the most accurate in the prediction of cirrhosis in the UK cohort (AUROC 0.87-0.89). CONCLUSIONS: This cross-sectional analysis of large, multicentre international datasets shows that current clinical prediction rules perform well in excluding cirrhosis with appropriately chosen cutoffs. These clinical prediction rules can be used in primary care to identify patients, particularly those who are white, female, and <65, unlikely to have cirrhosis so higher-risk patients maintain access to specialty care.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Brandman D, Boyle M, McPherson S, et al. Comparison of clinical prediction rules for ruling out cirrhosis in nonalcoholic fatty liver disease (NAFLD). Aliment Pharmacol Ther. 2022. PMID: 35302256. doi:10.1111/apt.16874

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。